U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Platinum-Refractory Primary Peritoneal Carcinoma

MedGen UID:
1791638
•Concept ID:
C5555197
•
Neoplastic Process

Definition

Primary peritoneal carcinoma that progresses during platinum therapy or within one month of completing the last platinum therapy. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVPlatinum-Refractory Primary Peritoneal Carcinoma

Professional guidelines

PubMed

Treatment Patterns and Health Outcomes in Platinum-Refractory or Platinum-Resistant Ovarian Cancer: A Retrospective Medical Record Review.
Parikh R, Kurosky SK, Udall M, Chang J, Cappelleri JC, Doherty JP, Kaye JA
Int J Gynecol Cancer 2018 May;28(4):738-748. doi: 10.1097/IGC.0000000000001222. PMID: 29538247
The current treatment of recurrent ovarian cancer.
Herzog TJ
Curr Oncol Rep 2006 Nov;8(6):448-54. doi: 10.1007/s11912-006-0074-9. PMID: 17040623

Recent clinical studies

Etiology

Efficacy and Safety of Weekly Paclitaxel Plus Vistusertib vs Paclitaxel Alone in Patients With Platinum-Resistant Ovarian High-Grade Serous Carcinoma: The OCTOPUS Multicenter, Phase 2, Randomized Clinical Trial.
Banerjee S, Giannone G, Clamp AR, Ennis DP, Glasspool RM, Herbertson R, Krell J, Riisnaes R, Mirza HB, Cheng Z, McDermott J, Green C, Kristeleit RS, George A, Gourley C, Lewsley LA, Rai D, Banerji U, Hinsley S, McNeish IA
JAMA Oncol 2023 May 1;9(5):675-682. doi: 10.1001/jamaoncol.2022.7966. PMID: 36928279Free PMC Article
HIPEC after neoadjuvant chemotherapy and interval debulking is associated with development of platinum-refractory or -resistant disease.
Jou J, Zimmer Z, Charo L, Yau C, Saenz C, Eskander R, McHale M, Veerapong J, Plaxe S, Binder P
Gynecol Oncol 2021 Apr;161(1):25-33. Epub 2020 Dec 6 doi: 10.1016/j.ygyno.2020.11.035. PMID: 33293046
Treatment Patterns and Health Outcomes in Platinum-Refractory or Platinum-Resistant Ovarian Cancer: A Retrospective Medical Record Review.
Parikh R, Kurosky SK, Udall M, Chang J, Cappelleri JC, Doherty JP, Kaye JA
Int J Gynecol Cancer 2018 May;28(4):738-748. doi: 10.1097/IGC.0000000000001222. PMID: 29538247
Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8).
Emons G, Kurzeder C, Schmalfeldt B, Neuser P, de Gregorio N, Pfisterer J, Park-Simon TW, Mahner S, Schröder W, Lück HJ, Heubner ML, Hanker L, Thiel F, Hilpert F
Gynecol Oncol 2016 Mar;140(3):450-6. Epub 2015 Dec 28 doi: 10.1016/j.ygyno.2015.12.025. PMID: 26731724
Positive experience of intraperitoneal chemotherapy followed by intravenous chemotherapy in heavily pretreated patients with suboptimal residual ovarian cancer and primary peritoneal cancer.
Nicoletto MO, Dalla Palma M, Donach ME, Gusella M, Cappetta A, Shams M, Marchet A, Nardin M, Pintacuda G, Di Maggio A, Marchesi M, Carli P, Fiduccia P, Artioli G, Nitti D
Tumori 2010 Nov-Dec;96(6):918-25. PMID: 21388052

Diagnosis

Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer.
Yuan Z, Zhang Y, Cao D, Shen K, Li Q, Zhang G, Wu X, Cui M, Yue Y, Cheng W, Wang L, Qu P, Tao G, Hou J, Sun L, Meng Y, Li G, Li C, Shi H, Chen Y
J Ovarian Res 2021 Jan 11;14(1):12. doi: 10.1186/s13048-020-00736-2. PMID: 33423683Free PMC Article
Treatment Patterns and Health Outcomes in Platinum-Refractory or Platinum-Resistant Ovarian Cancer: A Retrospective Medical Record Review.
Parikh R, Kurosky SK, Udall M, Chang J, Cappelleri JC, Doherty JP, Kaye JA
Int J Gynecol Cancer 2018 May;28(4):738-748. doi: 10.1097/IGC.0000000000001222. PMID: 29538247
Positive experience of intraperitoneal chemotherapy followed by intravenous chemotherapy in heavily pretreated patients with suboptimal residual ovarian cancer and primary peritoneal cancer.
Nicoletto MO, Dalla Palma M, Donach ME, Gusella M, Cappetta A, Shams M, Marchet A, Nardin M, Pintacuda G, Di Maggio A, Marchesi M, Carli P, Fiduccia P, Artioli G, Nitti D
Tumori 2010 Nov-Dec;96(6):918-25. PMID: 21388052
The current treatment of recurrent ovarian cancer.
Herzog TJ
Curr Oncol Rep 2006 Nov;8(6):448-54. doi: 10.1007/s11912-006-0074-9. PMID: 17040623
Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
Sabbatini P, Aghajanian C, Dizon D, Anderson S, Dupont J, Brown JV, Peters WA, Jacobs A, Mehdi A, Rivkin S, Eisenfeld AJ, Spriggs D
J Clin Oncol 2004 Nov 15;22(22):4523-31. doi: 10.1200/JCO.2004.12.043. PMID: 15542803

Therapy

Efficacy and Safety of Weekly Paclitaxel Plus Vistusertib vs Paclitaxel Alone in Patients With Platinum-Resistant Ovarian High-Grade Serous Carcinoma: The OCTOPUS Multicenter, Phase 2, Randomized Clinical Trial.
Banerjee S, Giannone G, Clamp AR, Ennis DP, Glasspool RM, Herbertson R, Krell J, Riisnaes R, Mirza HB, Cheng Z, McDermott J, Green C, Kristeleit RS, George A, Gourley C, Lewsley LA, Rai D, Banerji U, Hinsley S, McNeish IA
JAMA Oncol 2023 May 1;9(5):675-682. doi: 10.1001/jamaoncol.2022.7966. PMID: 36928279Free PMC Article
Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer.
Yuan Z, Zhang Y, Cao D, Shen K, Li Q, Zhang G, Wu X, Cui M, Yue Y, Cheng W, Wang L, Qu P, Tao G, Hou J, Sun L, Meng Y, Li G, Li C, Shi H, Chen Y
J Ovarian Res 2021 Jan 11;14(1):12. doi: 10.1186/s13048-020-00736-2. PMID: 33423683Free PMC Article
HIPEC after neoadjuvant chemotherapy and interval debulking is associated with development of platinum-refractory or -resistant disease.
Jou J, Zimmer Z, Charo L, Yau C, Saenz C, Eskander R, McHale M, Veerapong J, Plaxe S, Binder P
Gynecol Oncol 2021 Apr;161(1):25-33. Epub 2020 Dec 6 doi: 10.1016/j.ygyno.2020.11.035. PMID: 33293046
Treatment Patterns and Health Outcomes in Platinum-Refractory or Platinum-Resistant Ovarian Cancer: A Retrospective Medical Record Review.
Parikh R, Kurosky SK, Udall M, Chang J, Cappelleri JC, Doherty JP, Kaye JA
Int J Gynecol Cancer 2018 May;28(4):738-748. doi: 10.1097/IGC.0000000000001222. PMID: 29538247
The current treatment of recurrent ovarian cancer.
Herzog TJ
Curr Oncol Rep 2006 Nov;8(6):448-54. doi: 10.1007/s11912-006-0074-9. PMID: 17040623

Prognosis

Efficacy and Safety of Weekly Paclitaxel Plus Vistusertib vs Paclitaxel Alone in Patients With Platinum-Resistant Ovarian High-Grade Serous Carcinoma: The OCTOPUS Multicenter, Phase 2, Randomized Clinical Trial.
Banerjee S, Giannone G, Clamp AR, Ennis DP, Glasspool RM, Herbertson R, Krell J, Riisnaes R, Mirza HB, Cheng Z, McDermott J, Green C, Kristeleit RS, George A, Gourley C, Lewsley LA, Rai D, Banerji U, Hinsley S, McNeish IA
JAMA Oncol 2023 May 1;9(5):675-682. doi: 10.1001/jamaoncol.2022.7966. PMID: 36928279Free PMC Article
Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer.
Yuan Z, Zhang Y, Cao D, Shen K, Li Q, Zhang G, Wu X, Cui M, Yue Y, Cheng W, Wang L, Qu P, Tao G, Hou J, Sun L, Meng Y, Li G, Li C, Shi H, Chen Y
J Ovarian Res 2021 Jan 11;14(1):12. doi: 10.1186/s13048-020-00736-2. PMID: 33423683Free PMC Article
A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.
Penson RT, Moore KM, Fleming GF, Braly P, Schimp V, Nguyen H, Matulonis UA, Banerjee S, Haluska P, Gore M, Bodurka DC, Hozak RR, Joshi A, Xu Y, Schwartz JD, McGuire WP
Gynecol Oncol 2014 Sep;134(3):478-85. Epub 2014 Jul 10 doi: 10.1016/j.ygyno.2014.06.029. PMID: 25016924Free PMC Article
A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma.
Bauman JE, Arias-Pulido H, Lee SJ, Fekrazad MH, Ozawa H, Fertig E, Howard J, Bishop J, Wang H, Olson GT, Spafford MJ, Jones DV, Chung CH
Oral Oncol 2013 May;49(5):461-7. Epub 2013 Feb 4 doi: 10.1016/j.oraloncology.2012.12.016. PMID: 23384718Free PMC Article
Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma.
Weroha SJ, Oberg AL, Ziegler KL, Dakhilm SR, Rowland KM, Hartmann LC, Moore DF Jr, Keeney GL, Peethambaram PP, Haluska P
Gynecol Oncol 2011 Jul;122(1):116-20. Epub 2011 Apr 22 doi: 10.1016/j.ygyno.2011.03.030. PMID: 21514634Free PMC Article

Clinical prediction guides

Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer.
Yuan Z, Zhang Y, Cao D, Shen K, Li Q, Zhang G, Wu X, Cui M, Yue Y, Cheng W, Wang L, Qu P, Tao G, Hou J, Sun L, Meng Y, Li G, Li C, Shi H, Chen Y
J Ovarian Res 2021 Jan 11;14(1):12. doi: 10.1186/s13048-020-00736-2. PMID: 33423683Free PMC Article
A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.
Penson RT, Moore KM, Fleming GF, Braly P, Schimp V, Nguyen H, Matulonis UA, Banerjee S, Haluska P, Gore M, Bodurka DC, Hozak RR, Joshi A, Xu Y, Schwartz JD, McGuire WP
Gynecol Oncol 2014 Sep;134(3):478-85. Epub 2014 Jul 10 doi: 10.1016/j.ygyno.2014.06.029. PMID: 25016924Free PMC Article
Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer.
Colombo N, Kutarska E, Dimopoulos M, Bae DS, Rzepka-Gorska I, Bidzinski M, Scambia G, Engelholm SA, Joly F, Weber D, El-Hashimy M, Li J, Souami F, Wing P, Engelholm S, Bamias A, Schwartz P
J Clin Oncol 2012 Nov 1;30(31):3841-7. Epub 2012 Sep 17 doi: 10.1200/JCO.2011.38.8082. PMID: 22987083
Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
Matulonis UA, Sharma S, Ghamande S, Gordon MS, Del Prete SA, Ray-Coquard I, Kutarska E, Liu H, Fingert H, Zhou X, Danaee H, Schilder RJ
Gynecol Oncol 2012 Oct;127(1):63-9. Epub 2012 Jul 5 doi: 10.1016/j.ygyno.2012.06.040. PMID: 22772063
Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma.
Weroha SJ, Oberg AL, Ziegler KL, Dakhilm SR, Rowland KM, Hartmann LC, Moore DF Jr, Keeney GL, Peethambaram PP, Haluska P
Gynecol Oncol 2011 Jul;122(1):116-20. Epub 2011 Apr 22 doi: 10.1016/j.ygyno.2011.03.030. PMID: 21514634Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...